197
Participants
Start Date
November 30, 2010
Primary Completion Date
December 31, 2013
Study Completion Date
December 31, 2013
pegIFN
Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
pegIFNα-2a
Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
PegIFN lambda
Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
Entecavir
Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
Local Institution, Taipei
Local Institution, Taipei
Local Institution, Taoyuan District
Local Institution, Taichung
Local Institution, Tainan City
Local Institution, Kaohsiung City
Local Institution, Hong Kong
Local Institution, Tai Po
Local Institution, Camperdown
Local Institution, Westmead Nsw
Local Institution, Liverpool
Local Institution, Melbourne
Local Institution, Heidelberg Vic
Local Institution, Clayton Vic
Local Institution, Fremantle
Medical Procare, Pllc, Flushing
Office Of Sing Chan Md, Flushing
University Of Pittsburgh Medical Center, Pittsburgh
Local Institution, Hamburg
Gastro Center Of Maryland, Colombia
Mercy Medical Center, Baltimore
Duke University Medical Center, Durham
Atlanta Gastroenterology Associates, Llc, Atlanta
Local Institution, Hanover
Local Institution, Rennes
Local Institution, Florence
Local Institution, Frankfurt
Local Institution, Tübingen
Local Institution, Paris
Local Institution, Freiburg im Breisgau
Research And Education, Inc., San Diego
Local Institution, Clichy
Advanced Clinical Research Institute, Anaheim
Sc Clinical Research, Inc., Garden Grove
University Of California, Davis Medical Center, Sacramento
Oregon Health & Science University, Portland
Local Institution, Singapore
Local Institution, Singapore
Yale New Haven Hospital, New Haven
Heritage Medical Research Clinic, University Of Calgary, Calgary
Local Institution, Winnipeg
Toronto General Hospital, Toronto
Toronto Western Hospital University Health Network, Toronto
Local Institution, Nice
Local Institution, Shatin
Local Institution, Roma
Local Institution, Rotterdam
Local Institution, Chuncheon
Local Institution, Gyeonggi-do
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY